SE8801903L - PHOSPHORETIC HMG COA REDUCTION INHIBITOR, NEW INTERMEDIATE AND SET - Google Patents
PHOSPHORETIC HMG COA REDUCTION INHIBITOR, NEW INTERMEDIATE AND SETInfo
- Publication number
- SE8801903L SE8801903L SE8801903A SE8801903A SE8801903L SE 8801903 L SE8801903 L SE 8801903L SE 8801903 A SE8801903 A SE 8801903A SE 8801903 A SE8801903 A SE 8801903A SE 8801903 L SE8801903 L SE 8801903L
- Authority
- SE
- Sweden
- Prior art keywords
- compounds
- phosphoretic
- hmg coa
- new intermediate
- reduction inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000003529 anticholesteremic agent Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910000077 silane Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/36—Amides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents have the structure <IMAGE> including salts thereof, wherein R is OH, lower alkoxy or lower alkyl; R<x> is H or alkyl; X is -O- or -NH-; n is 1 or 2 Z is a hydrophobic anchor, such as <IMAGE> wherein the dotted lines represent optional double bonds. New intermediates used in preparing the above compounds, e.g. compounds in which the OH group is silane blocked, pharmaceutical compositions containing such compounds and a method for using such compounds to inhibit cholesterol biosynthesis are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5328187A | 1987-05-22 | 1987-05-22 | |
US10968087A | 1987-10-19 | 1987-10-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
SE8801903D0 SE8801903D0 (en) | 1988-05-20 |
SE8801903L true SE8801903L (en) | 1988-11-23 |
SE503210C2 SE503210C2 (en) | 1996-04-22 |
Family
ID=26731667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE8801903A SE503210C2 (en) | 1987-05-22 | 1988-05-20 | Phosphorus-containing HMG-CoA-Reductase Inhibitor, New Intermediates and Methods |
Country Status (24)
Country | Link |
---|---|
JP (1) | JP2680347B2 (en) |
KR (1) | KR880013958A (en) |
CN (1) | CN88103091A (en) |
AU (1) | AU610591B2 (en) |
BE (1) | BE1004193A3 (en) |
CH (1) | CH676984A5 (en) |
DE (1) | DE3817375C2 (en) |
DK (1) | DK277488A (en) |
ES (1) | ES2009918A6 (en) |
FI (1) | FI89493C (en) |
FR (1) | FR2615508B1 (en) |
GB (1) | GB2205837B (en) |
GR (1) | GR1000959B (en) |
HU (1) | HU205125B (en) |
IE (2) | IE63760B1 (en) |
IL (1) | IL86464A (en) |
IT (1) | IT1217685B (en) |
NL (1) | NL8801330A (en) |
NO (1) | NO882218L (en) |
NZ (1) | NZ224733A (en) |
PH (1) | PH25350A (en) |
PL (1) | PL154877B1 (en) |
PT (1) | PT87539B (en) |
SE (1) | SE503210C2 (en) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ224734A (en) * | 1987-05-22 | 1991-04-26 | Squibb & Sons Inc | Organophosphorus hmg-coa reductase inhibitors, and pharmaceutical compositions |
CA2007643A1 (en) * | 1989-02-01 | 1990-08-01 | Donald S. Karanewsky | Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination |
CA2042526A1 (en) * | 1990-06-11 | 1991-12-12 | Adeoye Y. Olukotun | Method for preventing a second heart attack employing an hmg coa reductase inhibitor |
US5202327A (en) * | 1991-07-10 | 1993-04-13 | E. R. Squibb & Sons, Inc. | Phosphorus-containing hmg-coa reductase inhibitors |
GB9126144D0 (en) * | 1991-12-10 | 1992-02-12 | British Bio Technology | Compounds |
US20010006644A1 (en) | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
SK3202001A3 (en) | 1998-09-17 | 2002-04-04 | Bristol Myers Squibb Co | Drug and a pharmaceutical composition for treating diabetes, insulin resistance, obesity, hyperglycemia, hyperinsulinemia or increased level |
US6774112B2 (en) | 2001-04-11 | 2004-08-10 | Bristol-Myers Squibb Company | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
PL377687A1 (en) | 2001-10-18 | 2006-02-06 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US6806381B2 (en) | 2001-11-02 | 2004-10-19 | Bristol-Myers Squibb Company | Process for the preparation of aniline-derived thyroid receptor ligands |
US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
ATE469645T1 (en) | 2002-10-23 | 2010-06-15 | Bristol Myers Squibb Co | GLYCINENITRIL BASED INHIBITORS OF DIPEPTIDYLPEPTIDASE IV |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
TW200504021A (en) | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
US7459474B2 (en) | 2003-06-11 | 2008-12-02 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US8158362B2 (en) | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
ES2399721T5 (en) | 2004-03-05 | 2016-05-25 | Univ Pennsylvania | Methods to treat disorders or diseases associated with hyperlipidemia and hypercholesterolemia minimizing adverse effects |
US7145040B2 (en) | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
AR051446A1 (en) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2) |
US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
US7589088B2 (en) | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7635699B2 (en) | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7220859B2 (en) | 2005-01-12 | 2007-05-22 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
WO2006076598A2 (en) | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7368458B2 (en) | 2005-01-12 | 2008-05-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US20060160850A1 (en) | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
EP2527337A1 (en) | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US7317012B2 (en) | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7572808B2 (en) | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
AR056155A1 (en) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | ANTAGONISTS OF NON-BASIC MELANINE CONCENTRATION HORMONE RECEIVER 1 |
EP2487154B1 (en) | 2005-10-31 | 2013-10-16 | Bristol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
PE20090185A1 (en) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR |
PE20090696A1 (en) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM |
WO2009023059A2 (en) | 2007-06-01 | 2009-02-19 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
WO2009018065A2 (en) | 2007-07-27 | 2009-02-05 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
JP5465177B2 (en) | 2007-09-20 | 2014-04-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Compounds and compositions as modulators of GPR119 activity |
PE20091928A1 (en) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS |
EA201101231A1 (en) | 2009-03-27 | 2012-06-29 | Бристол-Майерс Сквибб Компани | METHODS TO PREVENT OR REDUCE THE RISK OF MORTALITY |
WO2011014520A2 (en) | 2009-07-29 | 2011-02-03 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
IN2012DN02471A (en) | 2009-10-09 | 2015-08-21 | Irm Llc | |
RU2564901C2 (en) | 2009-11-13 | 2015-10-10 | Бристол-Майерс Сквибб Кампани | Compositions of metformin with reduced weight |
US8871264B2 (en) | 2009-11-13 | 2014-10-28 | Astrazeneca Ab | Immediate release tablet formulations |
CN102711739B (en) | 2009-11-13 | 2015-12-16 | 阿斯利康(瑞典)有限公司 | Bilayer tablet |
US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
EP2558461B1 (en) | 2010-04-14 | 2015-12-02 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
RU2016125229A (en) | 2010-07-09 | 2018-12-04 | БиЭйчВи ФАРМА, ИНК. | COMBINED DELIVERY SYSTEM WITH IMMEDIATE / SLOW-DELIVERY FOR MEDICINES WITH A SHORT HALF-HOUR, INCLUDING REMOGLYPHLOSIN |
US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
TWI631963B (en) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
WO2014052619A1 (en) | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
PT3489226T (en) | 2012-11-20 | 2021-03-02 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose cotransporter 1 |
US9593113B2 (en) | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
CN104610262B (en) * | 2013-11-01 | 2017-06-06 | 上海医药工业研究院 | Biphenyl compound, intermediate, preparation method, pharmaceutical composition and its application |
SG11201708323SA (en) | 2015-04-30 | 2017-11-29 | Harvard College | Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders |
JP2021530517A (en) | 2018-07-19 | 2021-11-11 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Methods of Treating HFpEF with Dapagliflozin, and Compositions Containing Dapagliflozin |
US10968192B2 (en) | 2018-09-26 | 2021-04-06 | Lexicon Pharmaceuticals, Inc. | Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA828650B (en) * | 1981-12-01 | 1983-09-28 | Hunt Chem Corp Philip A | Herbicidal compositions and method using phosphonalkanoic acids, esters and salts thereof |
FR2596393B1 (en) * | 1986-04-01 | 1988-06-03 | Sanofi Sa | HYDROXY-3 DIHYDROXYOXOPHOSPHORIO-4 BUTANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM |
NZ224734A (en) * | 1987-05-22 | 1991-04-26 | Squibb & Sons Inc | Organophosphorus hmg-coa reductase inhibitors, and pharmaceutical compositions |
-
1988
- 1988-05-20 HU HU882614A patent/HU205125B/en not_active IP Right Cessation
- 1988-05-20 ES ES8801610A patent/ES2009918A6/en not_active Expired
- 1988-05-20 IE IE154388A patent/IE63760B1/en not_active IP Right Cessation
- 1988-05-20 PH PH36956A patent/PH25350A/en unknown
- 1988-05-20 SE SE8801903A patent/SE503210C2/en not_active IP Right Cessation
- 1988-05-20 IL IL86464A patent/IL86464A/en not_active IP Right Cessation
- 1988-05-20 NO NO882218A patent/NO882218L/en unknown
- 1988-05-20 AU AU16508/88A patent/AU610591B2/en not_active Ceased
- 1988-05-20 GR GR880100331A patent/GR1000959B/en unknown
- 1988-05-20 GB GB8811929A patent/GB2205837B/en not_active Expired - Fee Related
- 1988-05-20 PT PT87539A patent/PT87539B/en not_active IP Right Cessation
- 1988-05-20 NZ NZ224733A patent/NZ224733A/en unknown
- 1988-05-20 FI FI882384A patent/FI89493C/en not_active IP Right Cessation
- 1988-05-20 DE DE3817375A patent/DE3817375C2/en not_active Expired - Fee Related
- 1988-05-20 IT IT20682/88A patent/IT1217685B/en active
- 1988-05-20 DK DK277488A patent/DK277488A/en not_active Application Discontinuation
- 1988-05-20 IE IE930324A patent/IE930324L/en unknown
- 1988-05-21 PL PL1988272597A patent/PL154877B1/en unknown
- 1988-05-21 KR KR1019880006020A patent/KR880013958A/en not_active Application Discontinuation
- 1988-05-21 JP JP63124809A patent/JP2680347B2/en not_active Expired - Lifetime
- 1988-05-21 CN CN198888103091A patent/CN88103091A/en active Pending
- 1988-05-24 BE BE8800566A patent/BE1004193A3/en not_active IP Right Cessation
- 1988-05-24 CH CH1967/88A patent/CH676984A5/fr not_active IP Right Cessation
- 1988-05-24 NL NL8801330A patent/NL8801330A/en not_active Application Discontinuation
- 1988-05-24 FR FR8806885A patent/FR2615508B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE8801903L (en) | PHOSPHORETIC HMG COA REDUCTION INHIBITOR, NEW INTERMEDIATE AND SET | |
EE03194B1 (en) | Compounds, their use as sweetening agents and process for their preparation | |
SE9201587D0 (en) | PHOSPHORETIC HMG-COA REDUCTION INHIBITORS, NEW INTERMEDIATES AND METHOD | |
EP0324421A3 (en) | Phosporus-containing squalene synthetase inhibitors, new intermediates and method | |
DK271287D0 (en) | TRANS-6- (2- (3- OR 4-CARBOXAMIDO-SUBSTITUTED PYRROL-1-YL) ALKYL) -4-HYDROXYPYRAN-2-ONES, THEIR PREPARATION AND PHARMACEUTICAL USE | |
FI855117A0 (en) | Segmented polyesters and similar compounds for use as soil release agents in detergent compositions | |
RU93050199A (en) | DEOXITAXOLS, METHODS OF THEIR PRODUCTION, INTERMEDIATE COMPOUNDS, PHARMACEUTICALS | |
DK438887D0 (en) | PROCEDURE FOR THE PREPARATION OF CHEMICAL COMPOUNDS | |
ATE107639T1 (en) | NEW ALKANOPHENONES. | |
EP0245990A3 (en) | Antihypercholesterolemic compounds | |
EP0108547A3 (en) | 1-bromoethyl ethyl carbonate and its use in the preparation of 1'-ethoxy-carbonyloxyethyl esters of penicillins and novel intermediates, methods for its preparation and 1-bromoethylchloroformate and 1-bromoethylbromoformate obtained as intermediates | |
EP0245003A3 (en) | Antihypercholesterolemic compounds | |
IE790771L (en) | 1,2-disubstituted pyrrolidine and piperidine compounds. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NUG | Patent has lapsed |